RS-102221
RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT2C receptor, with around 100x selectivity over the closely related 5-HT2A and 5-HT2B receptors. It has anxiolytic effects in animal studies, increases the effectiveness of SSRI antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-HT2C receptor in regulation of the dopamine signalling system in the brain.
Wikipage redirect
primaryTopic
RS-102221
RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT2C receptor, with around 100x selectivity over the closely related 5-HT2A and 5-HT2B receptors. It has anxiolytic effects in animal studies, increases the effectiveness of SSRI antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-HT2C receptor in regulation of the dopamine signalling system in the brain.
has abstract
RS-102221 is a drug developed ...... ignalling system in the brain.
@en
CAS number
185376-97-0
IUPAC name
N-{5-[5-(2,4-dioxo-1,3,8-triaz ...... luoromethyl)benzenesulfonamide
@en
PubChem
thumbnail
Wikipage page ID
20,565,643
Wikipage revision ID
727,568,962
ChEMBL
IUPHAR ligand
molecular weight
6.14632e+2
smiles
c4ccccc4SNccc2CCCCCNCCC13NCNC1=O
synonyms
RS-102,221; 8-[5-
Verifiedfields
verifiedrevid
407,718,072
subject
hypernym
comment
RS-102221 is a drug developed ...... ignalling system in the brain.
@en
label
RS-102221
@en